English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Identification of the anaplastic lymphoma kinase ( ALK ) gene has refined the classification of non‐small cell lung cancer ( NSCLC ) and promoted research on molecularly targeted drugs such as crizotinib, an  ALK  inhibitor with good efficacy, in  ALK ‐rearranged  NSCLC . At present, few studies have reported the efficacy of crizotinib in patients with  ALK ‐rearranged  NSCLC  with brain metastases. In a patient with  NSCLC  harboring  ALK ‐rearrangement who had brain metastases and poor performance status ( PS ), we obtained a durable response with crizotinib administered following multi‐line chemotherapy regimens.

thoracic cancer

Long‐lasting response to third‐line crizotinib treatment in a patient with non‐small cell lung cancer with brain metastases and poor performance status